Holen Sie sich die Stockscreener-App
0.785
3.09%
-0.025
Schlusskurs vom Vortag:
$0.81
Offen:
$0.8005
24-Stunden-Volumen:
417.98K
Relative Volume:
0.25
Marktkapitalisierung:
$94.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.4005
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
+5.02%
1M Leistung:
+11.46%
6M Leistung:
+65.96%
1J Leistung:
-39.15%
1-Tages-Spanne:
$0.78
$0.8199
1-Wochen-Bereich:
$0.75
$0.855
52-Wochen-Spanne:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
1601 TRAPELO ROAD, WALTHAM
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.785 | 97.17M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
What drives Invivyd Inc. stock priceHigh-octane financial growth - PrintWeekIndia
Is Invivyd Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
What analysts say about Invivyd Inc. stockOutstanding yields - Autocar Professional
Invivyd Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome - The Manila Times
Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group - Investing.com
Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group By Investing.com - Investing.com South Africa
Invivyd, Inc.'s (NASDAQ:IVVD) Shift From Loss To Profit - simplywall.st
How Invivyd Inc. stock performs during market volatilityFree Stock Market Swing Trading Strategies - Newser
Goldman Sachs Shines in Q2 2025 Earnings Call - The Globe and Mail
Why Invivyd Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Invivyd Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Why Shares of Nebius Group Are Rocketing Higher Today - The Globe and Mail
Invivyd Launches SPEAR Study for Long COVID Therapy - TipRanks
Invivyd forms research group to study monoclonal antibodies for Long COVID - Investing.com
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - TradingView
Invivyd (IVVD) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus
H.C. Wainwright maintains buy rating on Invivyd stock after positive data - Investing.com
Invivyd’s COVID-19 antibody shows promising safety profile in trial - Investing.com
Invivyd’s COVID-19 antibody shows promising safety profile in trial By Investing.com - Investing.com UK
Trading Day Triumph: Invivyd Inc (IVVD) Ends at 0.79, a -6.47 Surge/Plunge - DWinneX
COVID’s remaining biotech contenders navigate a dwindling market - Pharma Voice
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):